Image source: Getty Images
ASX reporting season will heat up this week as several big-names S&P/ASX 200 Index (ASX: XJO) shares hand in their full-year FY22 results.
Tomorrow, embattled funds management company Magellan Financial Group Ltd. (ASX: MFG) and annuities provider Challenger Ltd (ASX: CGF) will release their respective FY22 reports.
Meanwhile, Wednesday and Thursday promise to be busy with expected results from the likes of Origin Energy Ltd (ASX:ORG), Newcrest Mining Ltd (ASX: NCM) and Tabcorp Holdings Limited (ASX:TAH).
Despite the size and stature of the companies mentioned above, stealing the spotlight this week will be the following trio of ASX blue-chip shares.
The ASX’s largest company is set to reveal its FY22 results tomorrow morning.
BHP made headlines last week after announcing a non-binding indicative proposal to acquire copper miner OZ Minerals Limited (ASX: OZL). OZ Minerals quickly knocked back the $8.4 billion bid, with the board stating it “significantly undervalued” the business.
BHP offered $25 cash per share, representing a 32% premium to OZ Minerals’ last closing price at the time. This story will likely continue to play out over the coming weeks.
In the meantime, investors will be watching the extent of the Big Australian’s revenue and earnings growth in FY22. Free cash flow will also be in focus as this guides BHP’s all-important dividend. In February, the ASX miner declared a record interim dividend of US$1.50 per share.
The ASX’s healthcare market darling will lift the lid on its FY22 results on Wednesday.
Last week, CSL finalized its $16 billion acquisition of Vifor Pharma. But since the deal was completed after the end of the financial year, this won’t impact CSL’s FY22 results.
Instead, investors will be keeping a close eye on how CSL’s plasma collections are faring in a post-COVID world. After the pandemic put a clamp on plasma donations, industry data is showing that trading conditions for the plasma market are much improved.
CSL delivered 4% revenue growth in the first half of FY22 as the company’s plasma-derived products stalled. This was propelled up by CSL’s influenza vaccine business, which posted sales growth of 18%.
According to our Foolish reporting season calendar, toll road operator Transurban is expected to report its full-year results on Thursday.
Transurban last delivered an update when it released an investor day presentation in May. Large vehicle traffic continued to show resilience, supported by major construction projects and increased e-commerce activity.
Meanwhile, traffic volumes across airport-related corridors are seeing signs of recovery.
Investors will no doubt pay close attention to the latest traffic volumes and insights when Transurban reports on Thursday. Any commentary around the impact of fuel prices and inflation also won’t go unnoticed.
Unlike BHP and CSL, Transurban’s dividends won’t be in focus on Thursday. This is because the toll road operator already declared a final FY22 distribution of 26 cents per stapled security back in June.
This took Transurban’s total FY22 distribution to 41 cents per stapled security, up 12% compared to the distributions paid in FY21.